Macrophage migration inhibitory factor -173G/C gene polymorphism increases the risk of renal disease: A meta-analysis

Nephrology

Volumn 20, Issue 2, 2015, Pages 68-76

  Tong, Xiang ^a   He, Jie ^a   Liu, Sitong ^a   Peng, Shifeng ^a   Yan, Zhipeng ^a   Zhang, Yonggang ^b   Fan, Hong ^a  

^a SICHUAN UNIVERSITY   (China)

^b FIRST AFFILIATED HOSPITAL   (China)

Author keywords

glucocorticoid resistance; meta analysis; MIF; polymorphism; renal disease

Indexed keywords

GLUCOCORTICOID; MACROPHAGE MIGRATION INHIBITION FACTOR; ISOMERASE; MIF PROTEIN, HUMAN;

ALLELE; ARTICLE; ASIAN; CAUCASIAN; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; KIDNEY DISEASE; META ANALYSIS; NEPHROTIC SYNDROME; PRIORITY JOURNAL; RISK ASSESSMENT; ADULT; AGE; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; CHILD; ETHNOLOGY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; KIDNEY DISEASES; PHENOTYPE; PROGNOSIS; RISK; RISK FACTOR;

ADULT; AGE FACTORS; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHILD; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; KIDNEY DISEASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; NEPHROTIC SYNDROME; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84921517912     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12353     Document Type: Article

References (44)

1. Bloom BR, Bennett B,. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966; 153: 80-82.
2. Calandra T, Echtenacher B, Le Roy D, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat. Med. 2000; 6: 164-170.
3. Bach JP, Deuster O, Balzer Geldsetzer M, Meyer B, Dodel R, Bacher M,. The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer 2009; 115: 2031-2040.
4. Lolis E,. Glucocorticoid counter regulation: Macrophage migration inhibitory factor as a target for drug discovery. Curr. Opin. Pharmacol. 2001; 1: 662-668.
5. Imamura K, Nishihira J, Suzuki M, et al. Identification and immunohistochemical localization of macrophage migration inhibitory factor in human kidney. IUBMB Life 1996; 40: 1233-1242.
6. Nishino T, Bernhagen J, Shiiki H, Calandra T, Dohi K, Bucala R,. Localization of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Mol. Med. 1995; 1: 781.
7. Bernhagen J, Calandra T, Mitchell R, et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993; 365: 756-759.
8. Shen Y, Guo S, Yang T, et al. The -173 G/C polymorphism of the MIF gene and inflammatory bowel disease risk: A meta-analysis. Int. J. Mol. Sci. 2013; 14: 11392-11401.
9. Sadki K, Lamsyah H, Rueda B, et al. Analysis of MIF, FCGR2A and FCGR3A gene polymorphisms with susceptibility to pulmonary tuberculosis in Moroccan population. J. Genet. Genomics 2010; 37: 257-264.
10. Takahashi N, Nishihira J, Sato Y, et al. Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol. Med. 1998; 4: 707-714.
11. Berdeli A, Mir S, Ozkayin N, Serdaroglu E, Tabel Y, Cura A,. Association of macrophage migration inhibitory factor -173C allele polymorphism with steroid resistance in children with nephrotic syndrome. Pediatr. Nephrol. 2005; 20: 1566-1571.
12. Tripathi G, Borkar M, Akhter A, Sankhwar SN, Sharma RK, Agrawal S,. Association of proinflammatory cytokines with end stage renal disease. Cytokine 2010; 50: 278-283.
13. Sasaki S, Nishihira J, Ishibashi T, et al. Transgene of MIF induces podocyte injury and progressive mesangial sclerosis in the mouse kidney. Kidney Int. 2004; 65: 469-481.
14. Lan HY, Yang N, Nikolic-Paterson DJ, et al. Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int. 2000; 57: 499-509.
15. Gao XH, Zhang GY, Wang Y, Zhang HY,. Correlations of MTHFR 677C> T polymorphism with cardiovascular disease in patients with end-stage renal disease: A meta-analysis. PLoS ONE 2014; 9: e102323.
16. Xue C, Zhou CC, Sun LJ, et al. Effects of endothelial nitric oxide synthase gene on end stage renal disease progression in autosomal dominant polycystic kidney disease. Nephrology 2014; 19: 630-637.
17. ͆wierczewska M, Ostalska-Nowicka D, Kempisty B, Szczepankiewicz A, Nowicki M,. Polymorphic variants of MIF gene and prognosis in steroid therapy in children with idiopathic nephrotic syndrome. Acta Biochim. Pol. 2014; 61: 67-75.
18. Vivarelli M, D'Urbano LE, Stringini G, et al. Association of the macrophage migration inhibitory factor -173∗C allele with childhood nephrotic syndrome. Pediatr. Nephrol. 2008; 23: 743-748.
19. Nalbantoglu S, Tabel Y, Mir S, Berdeli A,. Lack of association between macrophage migration inhibitory factor gene promoter (- 173 G/C) polymorphism and childhood Henoch-Schönlein purpura in Turkish patients. Cytokine 2013; 62: 160-164.
20. Amoli MM, Martin J, Miranda-Filloy JA, Garcia-Porrua C, Ollier WE, Gonzalez-Gay MA,. Lack of association between macrophage migration inhibitory factor gene (-173 G/C) polymorphism and cutaneous vasculitis. Clin. Exp. Rheumatol. 2006; 24: 576-579.
21. Sreih A, Ezzeddine R, Leng L, et al. Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. Arthritis Rheum. 2011; 63: 3942-3951.
22. Zhao R, Yao WJ,. The Functions and Clinical studies of Macrophage Migration Inhibitory Factor (Chinese). Prog. Physiol. Sci. 2014; 45: 93-99.
23. Guo X,. Correlation between -173G/C gene polymorphism of macrophage migration inhibitory factor and henoch-schonle in purpura nephritis (Chinese). Nanchang University (Dissertation). 2010.
24. Choi HJ, Cho HY, Ro H, et al. Polymorphisms of the MDR1 and MIF genes in children with nephrotic syndrome. Pediatr. Nephrol. 2011; 26: 1981-1988.
25. Guo X, Hu BJ, Zhou HP, Fu R, Liu H,. Correlation between -173G/C Gene Polymorphism of Macrophage Migration Inhibitory Factor and Henoch-Schonle in Purpura Nephritis (Chinese). J. Appl. Clin. Pediatr. 2010; 25: 333-335.
26. Yu SJ, Gan H,. Reaearch on the association of MIF with diabetic nephrophthy (Chinese). Chongqing Medical University (Dissertation), 2010.
27. Campbell RC, Ruggenenti P, Remuzzi G,. Halting the progression of chronic nephropathy. J. Am. Soc. Nephrol. 2002; 13: S190-195.
28. Lysaght MJ,. Maintenance dialysis population dynamics: Current trends and long-term implications. J. Am. Soc. Nephrol. 2002; 13: S37-S40.
29. Llach F,. Thromboembolic complications in nephrotic syndrome. Coagulation abnormalities, renal vein thrombosis, and other conditions. Postgrad. Med. 1984; 76: 111-114. 116-18, 121-3.
30. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY,. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004; 351: 1296-1305.
31. Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2003 Annual Data Report: Atlas of end-stage renal disease in the United States. Am. J. Kidney Dis. 2003; 42: A5-7, S1-230.
32. Trifillis AL, Donnenberg MS, Cui X, et al. Binding to and killing of human renal epithelial cells by hemolytic P-fimbriated E. coli. Kidney Int. 1994; 46: 1083-1091.
33. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N. Engl. J. Med. 1996; 334: 13-18.
34. Kanwar YS, Wada J, Sun L, et al. Diabetic nephropathy: Mechanisms of renal disease progression. Exp. Biol. Med. 2008; 233: 4-11.
35. McCluskey R, Klassen J,. Immunologically mediated glomerular, tubular and interstitial renal disease. N. Engl. J. Med. 1973; 288: 564-570.
36. Kang D-H, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J. Am. Soc. Nephrol. 2002; 13: 2888-2897.
37. Noiri E, Satoh H, Taguchi JI, et al. Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension 2002; 40: 535-540.
38. Freedman BI, Hicks PJ, Bostrom MA, et al. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int. 2009; 75: 736-745.
39. Mitchell R, Bacher M, Bernhagen J, Pushkarskaya T, Seldin MF, Bucala R,. Cloning and characterization of the gene for mouse macrophage migration inhibitory factor (MIF). J. Immunol. 1995; 154: 3863-3870.
40. Bacher M, Metz CN, Calandra T, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc. Natl Acad. Sci. U.S.A. 1996; 93: 7849-7854.
41. Satoskar AR, Bozza M, Sosa MR, Lin G, David JR,. Migration-inhibitory factor gene-deficient mice are susceptible to cutaneous Leishmania major infection. Infect. Immun. 2001; 69: 906-911.
42. Shiroeda H, Tahara T, Shibata T, et al. Functional promoter polymorphisms of macrophage migration inhibitory factor in peptic ulcer diseases. Int. J. Mol. Med. 2010; 26: 707-711.
43. Li H, Zang J, Wang P, Dai L, Zhang J, Wang K,. Gastric cancer susceptibility in gastric cancer relatives: Attributable risks of Macrophage migration inhibitory factor promoter polymorphism and Helicobacter pylori. Cytokine 2012; 60: 346-351.
44. Santos L, Hall P, Metz C, Bucala R, Morand E,. Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: Interaction with glucocorticoids. Clin. Exp. Immunol. 2001; 123: 309-314.